Drug intelligence / Profile preview

JZ-001

Development stage: Preclinical
Lead developer: 四川九章生物化工科技发展有限公司
Modality: Small Molecules

Overview

JZ-001 is a small molecule natural product derivative, specifically a derivative of chlorogenic acid, under development by Sichuan J.Z. Bio-chemical (also known as Jiu Zhang Biotech). It is positioned in the company's pipeline as a next-generation follow-up to their lead candidate, injectable chlorogenic acid. While the parent compound is being evaluated in Phase 1 clinical trials for various squamous cell carcinomas (including lung, esophageal, and cervical) and has received FDA Orphan Drug designation for glioblastoma, JZ-001 is currently in the preclinical stage. The specific therapeutic targets and mechanism of action for JZ-001 have not yet been disclosed, but it is expected to leverage the biological activity of the chlorogenic acid scaffold in oncology or metabolic indications.

Other names: Chlorogenic Acid Derivative绿原酸衍生物

Beyond the preview

Go deeper on JZ-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JZ-001.

Explore the full profile